Targeting the mitogen-activated protein kinase cascade to treat cancer
JS Sebolt-Leopold, R Herrera - Nature reviews cancer, 2004 - nature.com
JS Sebolt-Leopold, R Herrera
Nature reviews cancer, 2004•nature.comThe RAS–mitogen activated protein kinase (MAPK) signalling pathway has long been
viewed as an attractive pathway for anticancer therapies, based on its central role in
regulating the growth and survival of cells from a broad spectrum of human tumours. Small-
molecule inhibitors designed to target various steps of this pathway have entered clinical
trials. What have we recently learned about their safety and effectiveness? Will the MAPK
pathway prove amenable to therapeutic intervention?
viewed as an attractive pathway for anticancer therapies, based on its central role in
regulating the growth and survival of cells from a broad spectrum of human tumours. Small-
molecule inhibitors designed to target various steps of this pathway have entered clinical
trials. What have we recently learned about their safety and effectiveness? Will the MAPK
pathway prove amenable to therapeutic intervention?
Abstract
The RAS–mitogen activated protein kinase (MAPK) signalling pathway has long been viewed as an attractive pathway for anticancer therapies, based on its central role in regulating the growth and survival of cells from a broad spectrum of human tumours. Small-molecule inhibitors designed to target various steps of this pathway have entered clinical trials. What have we recently learned about their safety and effectiveness? Will the MAPK pathway prove amenable to therapeutic intervention?
nature.com